



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_270_26

You asked:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drugs from the Dermatology and Rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Appendix A

Q1a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of January 2026 to the end of March 2026?

Please use the latest available 3 months if January to March is not available and specify which 3 months have been used.

Drug Name	Dermatology	Rheumatology
Adalimumab		
Apremilast		
Bimekizumab		
Brodalumab		
Certolizumab Pegol		
Deucravacitinib		
Etanercept		
Etrasimod		
Filgotinib		
Golimumab		
Guselkumab		
Infliximab (Biosimilars)		
Infliximab (Remicade)		
Ixekizumab		
Mirikizumab		
Ozanimod		
Risankizumab		
Secukinumab		
Tildrakizumab		
Tofacitinib		
Upadacitinib		

Ustekinumab		
Vedolizumab		

Our response:

Please find the patient numbers for the selected preparations below. The preparations were issued between January 2026 and the end of March 2026.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Drug Name	Dermatology	Rheumatology
Adalimumab	77	565
Apremilast	14	**
Bimekizumab	28	58
Brodalumab	0	0
Certolizumab Pegol	9	68
Deucravacitinib	24	0
Etanercept	**	272
Etrasimod	0	0
Filgotinib	0	18
Golimumab	0	56
Guselkumab	64	**
Infliximab (Biosimilars)	**	26
Infliximab (Remicade)	0	0
Ixekizumab	16	26
Mirikizumab	0	0
Ozanimod	0	0
Risankizumab	71	0
Secukinumab	9	91
Tildrakizumab	11	0
Tofacitinib	0	9
Upadacitinib	15	46
Ustekinumab	47	20
Vedolizumab	0	0